Matthew J. Sale

This study identifies ELV-3111, a Type 1 RAF inhibitor that selectively suppresses MAPK and tumor growth by exploiting distinct binding kinetics, showing efficacy in RAS-mutant and BRAF-mutant models.

This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.